A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

An Open-Label, Singe Arm, Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab (Tecentriq) in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03922997
• Other study ID #: ML40471
• Status: Completed
• Phase: Phase 3
• Start date: July 3, 2019
• Est. completion date: August 11, 2022

Study information

• Verified date: September 2022
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase III, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC) who have progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy or after anti-PD-1 as monotherapy).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: August 11, 2022
• Est. primary completion date: August 11, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically documented Stage IIIb or Stage IV NSCLC that has progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy or after anti-PD-1 as monotherapy). Patients with a previously detected EGFR mutation or ALK fusion oncogene will be excluded from this study. Overall, patients should not have received more than two lines of systemic chemotherapy. Patients who have discontinued first-line or second-line systemic chemotherapy, targeted therapy, or anti-PD-1 therapy due to intolerance are also eligible.

• The last dose of prior systemic anticancer therapy must have been administered = 21 days prior to the first study treatment.

• The last dose of prior anti-PD-1 therapy must have been administered

• Measurable disease, as defined by Response Evaluation Criteria for Solid Tumors, Version 1.1 (RECIST v1.1)

• Patients with asymptomatic CNS metastases (treated or untreated), as determined by CT or MRI evaluation during screening and prior radiographic evaluation, are eligible

• ECOG performance status 0, 1, or 2

• Life expectancy = 12 weeks

• Adequate hematologic and end-organ function

• For women of childbearing potential: agreement to remain abstinent or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab

• Patients must have recovered from all acute toxicities from previous therapy, excluding alopecia and toxicities related to prior anti-PD-1-therapy

Exclusion Criteria:

• Patients with EGFR mutation or ALK fusion oncogene

• Symptomatic CNS metastases

• Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for = 2 weeks prior to the first study treatment

• Leptomeningeal disease

• Uncontrolled pericardial effusion or ascites requiring recurrent drainage procedures

• Pregnant or lactating, or intending to become pregnant during the study

• Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, including significant liver disease

• Significant cardiovascular disease

• Significant renal disorder requiring dialysis or indication for renal transplant

• Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation

• Major surgical procedure within 4 weeks prior to study treatment initiation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis

• Prior allogeneic stem cell or solid organ transplantation

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing City
China	Sichuan Cancer Hospital	Chengdu City
China	Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department	Hangzhou City
China	Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy	Harbin
China	Taizhou Hospital of Zhejiang Province	Linhai
China	Fudan University Shanghai Cancer Center; Medical Oncology	Shanghai City
China	Cancer Hospital Affliated to Xinjiang Medical University	Urumqi City

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serious Adverse Event Incidence Rates	The incidence of serious adverse events (SAEs) related to atezolizumab.	Baseline up to approximately 3 years
Secondary	Overall Survival (OS) Rate	Overall survival (OS) rate at 2 years, defined as the proportion of patients remaining alive 2 years after initiation of study treatment	Baseline to 2 years
Secondary	OS	Overall survival (OS), defined as the time from initiation of study treatment to death from any cause	Baseline up to approximately 3 years
Secondary	Progression-Free Survival (PFS)	Progression-free survival (PFS), defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first.	Baseline up to approximately 3 years
Secondary	Objective Response Rate (ORR)	Objective response rate (ORR), defined as the percentage of patients who attain complete response (CR) or partial response (PR) according to RECIST v1.1 and also by disease status evaluated by the investigator according to modified RECIST	Baseline up to approximately 3 years
Secondary	Duration of Response (DOR)	Duration of response (DOR), defined as the time from initial response to disease progression or death among patients who have experienced a CR or PR (unconfirmed) during the study.	Baseline up to approximately 3 years
Secondary	EQ-5D-5L Index-Based and VAS scores	EQ-5D-5L, EuroQol 5-Dimension Questionnaire is a self-report health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. The EuroQol EQ-5D has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort and anxiety/depression, as well as a visual analog scale (VAS) that measures health state. Overall scores range from 0 to 1, with low scores representing a higher level of dysfunction.	Day 1 of first 3 cycles, then with tumor assessments every 6 weeks for 48 weeks from study treatment date; thereafter every 9 weeks until progressive disease or until treatment discontinuation (up to approximately 3 years)
Secondary	EORTC QLQ-LC13 score	EORTC QLQ-LC13, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module will be used to assess self-reported outcomes. EORTC QLQ-LC13 includes 13 items that address key lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related adverse effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. The dysphagia scale is multi-item, while the rest are single-item scales.	Day 1 of first 3 cycles, then with tumor assessments every 6 weeks for 48 weeks from study treatment date; thereafter every 9 weeks until progressive disease or until treatment discontinuation (up to approximately 3 years)